Shundong Cang
A5039405375- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- RNA and protein synthesis mechanisms
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Circular RNAs in diseases
- Histone Deacetylase Inhibitors Research
- Esophageal Cancer Research and Treatment
- Chronic Myeloid Leukemia Treatments
- MicroRNA in disease regulation
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- RNA Research and Splicing
- Ferroptosis and cancer prognosis
Henan Provincial People's Hospital
2017-2025
Zhengzhou University
2016-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2025
Henan University
2018-2024
Zhengzhou People's Hospital
2010-2023
Peking University
2019
Peking University Cancer Hospital
2019
New York Medical College
2008-2016
Westchester Medical Center
2009
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve ESCC were randomized (1:1) to receive toripalimab or placebo in combination paclitaxel plus cisplatin (TP) every weeks up 6 cycles, followed by maintenance. At prespecified final analysis of progression-free survival (PFS), a significant improvement PFS observed arm over (hazard ratio...
IntroductionSintilimab, an anti–programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted randomized, double-blind, 3 study to compare the safety of sintilimab with placebo, both combination such chemotherapy (ClinicalTrials.gov: NCT03607539).MethodsA total 397 patients previously untreated, locally advanced or metastatic without sensitizing EGFR anaplastic lymphoma kinase genomic aberration were...
Importance Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, few effective treatments available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death (PD-1), combination with chemotherapy, has demonstrated promising efficacy. Objective To compare overall survival of patients unresectable locally advanced or metastatic gastric who were treated sintilimab chemotherapy vs placebo chemotherapy....
IntroductionSintilimab plus chemotherapy significantly prolonged progression-free survival (PFS) compared with alone in nonsquamous NSCLC the ORIENT-11 study. Updated overall (OS) and PFS data corresponding biomarker analyses are reported here.MethodsIn this study, a total of 397 patients previously untreated, locally advanced or metastatic were assigned to sintilimab combination treatment (combo) group placebo group. The stratified by programmed death-ligand 1 (PD-L1) expression levels....
BACKGROUNDExosomes contain proteins, lipids, and biological molecules such as DNA RNA.Nucleic acids in exosomes are a group of that can act biomarkers.Currently, there many reports on exosomal microRNAs, which ideal biomarkers for the early diagnosis cancer.However, few role microRNAs prognosis hepatocellular carcinoma (HCC). AIMTo understand mechanism microRNA-224 (miR-224) development HCC evaluate its diagnostic prognostic value. METHODSCell culture transfection miRNA-224, real-time...
Abstract Background Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall (OS) compared to alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with LUSC. However, predictive biomarkers remain unknown. Methods Tumor tissue samples at baseline, peripheral blood baseline (pretreatment) after two cycles (on-treatment) were...